---
schema_version: "secwatch.filing_event.v1"
accession: "0001699031-26-000009"
form_type: "8-K"
ticker: "GRAL"
cik: "0001699031"
company_name: "GRAIL, Inc."
filed_at: "2026-02-19T23:59:59+00:00"
generated_at: "2026-05-16T01:46:57.896439+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# NHS-Galleri trial misses primary endpoint but shows Stage IV reduction; Q4 rev $43.6M

## Summary
- Primary endpoint of significant Stage III-IV reduction not met; substantial Stage IV reduction observed across 12 deadly cancers.
- Adding Galleri to standard care yielded four-fold higher cancer detection rate and increased Stage I-II detection of deadly cancers.
- Q4 total revenue $43.6M (+14% YoY); US Galleri revenue $41.3M (+31% YoY). Full year revenue $147.2M (+17% YoY).
- Net loss Q4 $99.2M (incl. $34.6M amort.); full year net loss $408.4M (incl. $138.3M amort. and $28M impairment).
- Galleri PMA submitted to FDA; U.S. sales force to expand based on NHS-Galleri and PATHFINDER 2 results.

## SEC filing metadata
- accession: 0001699031-26-000009
- form_type: 8-K
- ticker: GRAL
- cik: 0001699031
- company_name: GRAIL, Inc.
- filed_at: 2026-02-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699031/000169903126000009/0001699031-26-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699031/000169903126000009/gral-20260219.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001699031-26-000009
- JSON: https://secwatch.observer/filing/0001699031-26-000009.json
- Plain text: https://secwatch.observer/filing/0001699031-26-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.